Citations to this article
Abstract
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant or digenic disorder linked to derepression of the toxic DUX4 gene in muscle. There is currently no pharmacological treatment. The emergence of DUX4 enabled development of cell and animal models that could be used for basic and translational research. Since DUX4 is toxic, animal model development has been challenging, but progress has been made, revealing that tight regulation of DUX4 expression is critical for creating viable animals that develop myopathy. Here, we report such a model — the tamoxifen-inducible FSHD mouse model called TIC-DUX4. Uninduced animals are viable, born in Mendelian ratios, and overtly indistinguishable from WT animals. Induced animals display significant DUX4-dependent myopathic phenotypes at the molecular, histological, and functional levels. To demonstrate the utility of TIC-DUX4 mice for therapeutic development, we tested a gene therapy approach aimed at improving muscle strength in DUX4-expressing muscles using adeno-associated virus serotype 1.Follistatin (AAV1.Follistatin), a natural myostatin antagonist. This strategy was not designed to modulate DUX4 but could offer a mechanism to improve muscle weakness caused by DUX4-induced damage. AAV1.Follistatin significantly increased TIC-DUX4 muscle mass and strength even in the presence of DUX4 expression, suggesting that myostatin inhibition may be a promising approach to treat FSHD-associated weakness. We conclude that TIC-DUX4 mice are a relevant model to study DUX4 toxicity and, importantly, are useful in therapeutic development studies for FSHD.
Authors
Carlee R. Giesige, Lindsay M. Wallace, Kristin N. Heller, Jocelyn O. Eidahl, Nizar Y. Saad, Allison M. Fowler, Nettie K. Pyne, Mustafa Al-Kharsan, Afrooz Rashnonejad, Gholamhossein Amini Chermahini, Jacqueline S. Domire, Diana Mukweyi, Sara E. Garwick-Coppens, Susan M. Guckes, K. John McLaughlin, Kathrin Meyer, Louise R. Rodino-Klapac, Scott Q. Harper
Citation information
Citations to this article (52)
| Title and authors | Publication | Year |
|---|---|---|
|
Iron supplementation alleviates pathologies in a mouse model of facioscapulohumeral muscular dystrophy
Kodai Nakamura, Huascar-Pedro Ortuste-Quiroga, Naoki Horii, Shin Fujimaki, Toshiro Moroishi, Keiichi I. Nakayama, Shinjiro Hino, Yoshihiko Saito, Ichizo Nishino, Yusuke Ono |
Journal of Clinical Investigation | 2025 |
|
Estrogen rescues muscle regeneration impaired by DUX4 in a humanized xenograft mouse model.
Maiullari S, Mele G, Calandra P, di Blasio G, Valentini S, Torcinaro A, Manni I, Teveroni E, Mancino F, Proietti L, Maiullari F, Pesavento M, Giorgini L, Putti S, Rizzi R, Bortolani S, Scavizzi F, Raspa M, Ricci E, Piaggio G, Gargioli C, Pontecorvi A, Luvisetto S, Mazzone M, Deidda G, Moretti F |
Cell death & disease | 2025 |
|
A systemically deliverable lipid-conjugated siRNA targeting DUX4 as an facioscapulohumeral muscular dystrophy therapeutic
Daman K, Yan J, Biscans A, Echeverria D, Shmushkovich T, Wolfson A, Alterman JF, Khvorova A, Emerson CP Jr |
Molecular Therapy. Methods & Clinical Development | 2025 |
|
Sarcopenia in chronic obstructive pulmonary disease: mechanisms, diagnosis, and management strategies
Khan MH, Fatima M, Adnan A, Jawaid A, Hassan SM, Talal M, Rahim S, Mughal ZU, Patel AO, Singh AK |
Annals of Medicine and Surgery | 2025 |
|
DUX4 at 25: how it emerged from “junk DNA” to become the cause of facioscapulohumeral muscular dystrophy
Belayew A, Rosa AL, Zammit PS |
Skeletal Muscle | 2025 |
|
FSHD muscle shows perturbation in fibroadipogenic progenitor cells, mitochondrial function and alternative splicing independently of inflammation.
Engquist EN, Greco A, Joosten LAB, van Engelen BGM, Zammit PS, Banerji CRS |
Human Molecular Genetics | 2024 |
|
Challenges and Considerations of Preclinical Development for iPSC-Based Myogenic Cell Therapy
Sun C, Serra C, Kalicharan BH, Harding J, Rao M |
Cells | 2024 |
|
Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions.
Wetzlich B, Nyakundi BB, Yang J |
Molecular and cellular biochemistry | 2024 |
|
Molecular, Histological, and Functional Changes in Acta1-MCM;FLExDUX4/+ Mice
Sohn S, Reid S, Bowen M, Corbex E, Le Gall L, Sidlauskaite E, Hourde C, Morel B, Mariot V, Dumonceaux J |
International Journal of Molecular Sciences | 2024 |
|
Have a Little Heart (or Not): Highly Minimized Skeletal Muscle Regulatory Cassettes with Low or No Activity in the Heart
Himeda CL, Jones TI, Jones PL |
Human Gene Therapy | 2024 |
|
Current Strategies of Muscular Dystrophy Therapeutics: An Overview.
Lim KRQ, Yokota T |
Methods in molecular biology (Clifton, N.J.) | 2023 |
|
Flavones provide resistance to DUX4-induced toxicity via an mTor-independent mechanism
Cohen J, Huang S, Koczwara K, Ho V, Woodman K, Lek A, Arbiser J, Lek M, DeSimone A |
Research square | 2023 |
|
Single-cell and spatial transcriptomics identify a macrophage population associated with skeletal muscle fibrosis
Coulis G, Jaime D, Guerrero-Juarez C, Kastenschmidt JM, Farahat PK, Nguyen Q, Pervolarakis N, McLinden K, Thurlow L, Movahedi S, Duarte J, Sorn A, Montoya E, Mozaffar I, Dragan M, Othy S, Joshi T, Hans CP, Kimonis V, MacLean AL, Nie Q, Wallace LM, Harper SQ, Mozaffar T, Hogarth MW, Bhattacharya S, Jaiswal JK, Golann DR, Su Q, Kessenbrock K, Stec M, Spencer MJ, Zamudio JR, Villalta SA |
2023 | |
|
Sarcopenia in chronic kidney disease: from bench to bedside
Kim DW, Song SH |
The Korean Journal of Internal Medicine | 2023 |
|
Human DUX4 and porcine DUXC activate similar early embryonic programs in pig muscle cells: implications for preclinical models of FSHD
Nip Y, Bennett SR, Smith AA, Jones TI, Jones PL, Tapscott SJ |
Human Molecular Genetics | 2023 |
|
Single-cell and spatial transcriptomics identify a macrophage population associated with skeletal muscle fibrosis
Coulis G, Jaime D, Guerrero-Juarez C, Kastenschmidt JM, Farahat PK, Nguyen Q, Pervolarakis N, McLinden K, Thurlow L, Movahedi S, Hughes BS, Duarte J, Sorn A, Montoya E, Mozaffar I, Dragan M, Othy S, Joshi T, Hans CP, Kimonis V, MacLean AL, Nie Q, Wallace LM, Harper SQ, Mozaffar T, Hogarth MW, Bhattacharya S, Jaiswal JK, Golann DR, Su Q, Kessenbrock K, Stec M, Spencer MJ, Zamudio JR, Villalta SA |
Science Advances | 2023 |
|
Flavones provide resistance to DUX4-induced toxicity via an mTor-independent mechanism
Cohen J, Huang S, Koczwara KE, Woods KT, Ho V, Woodman KG, Arbiser JL, Daman K, Lek M, Emerson CP Jr, DeSimone AM |
Cell Death and Disease | 2023 |
|
Meeting report: the 2021 FSHD International Research Congress
S Jagannathan, J de Greef, L Hayward, K Yokomori, D Gabellini, K Mul, S Sacconi, J Arjomand, J Kinoshita, S Harper |
Skeletal Muscle | 2022 |
|
Persistent Fibroadipogenic Progenitor Expansion Following Transient DUX4 Expression Provokes a Profibrotic State in a Mouse Model for FSHD
D Bosnakovski, D Oyler, A Mitanoska, M Douglas, E Ener, A Shams, M Kyba |
International journal of molecular sciences | 2022 |
|
Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression
Lu-Nguyen N, Dickson G, Malerba A, Popplewell L |
Biomedicines | 2022 |
|
Transplantation of PSC-derived myogenic progenitors counteracts disease phenotypes in FSHD mice
Azzag K, Bosnakovski D, Tungtur S, Salama P, Kyba M, Perlingeiro RC |
npj Regenerative Medicine | 2022 |
|
New intranasal and injectable gene therapy for healthy life extension
Jaijyan DK, Selariu A, Cruz-Cosme R, Tong M, Yang S, Stefa A, Kekich D, Sadoshima J, Herbig U, Tang Q, Church G, Parrish EL, Zhu H |
Proceedings of the National Academy of Sciences | 2022 |
|
Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease
Thomas FP, Brannagan TH III, Butterfield RJ, Desai U, Habib AA, Herrmann DN, Eichinger KJ, Johnson NE, Karam C, Pestronk A, Quinn C, Shy ME, Statland JM, Subramony SH, Walk D, Stevens-Favorite K, Miller B, Leneus A, Fowler M, van de Rijn M, Attie KM |
Neurology | 2022 |
|
Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy
Statland JM, Campbell C, Desai U, Karam C, Díaz\u2010Manera J, Guptill JT, Korngut L, Genge A, Tawil RN, Elman L, Joyce NC, Wagner KR, Manousakis G, Amato AA, Butterfield RJ, Shieh PB, Wicklund M, Gamez J, Bodkin C, Pestronk A, Weihl CC, Vilchez\u2010Padilla JJ, Johnson NE, Mathews KD, Miller B, Leneus A, Fowler M, van de Rijn M, Attie KM |
Muscle & Nerve | 2022 |
|
TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective.
Nixon BG, Gao S, Wang X, Li MO |
Nature reviews. Immunology | 2022 |
|
A stromal progenitor and ILC2 niche promotes muscle eosinophilia and fibrosis-associated gene expression
JM Kastenschmidt, G Coulis, PK Farahat, P Pham, R Rios, TT Cristal, AH Mannaa, RE Ayer, R Yahia, AA Deshpande, BS Hughes, AK Savage, CR Giesige, SQ Harper, RM Locksley, T Mozaffar, SA Villalta |
Cell Reports | 2021 |
|
Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model
N Lu-Nguyen, A Malerba, S Herath, G Dickson, L Popplewell |
Human Molecular Genetics | 2021 |
|
Advances in research on pharmacotherapy of sarcopenia
Y Feike, L Zhijie, C Wei |
2021 | |
|
Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models
AM Nunes, M Ramirez, TI Jones, PL Jones |
Disease models & mechanisms | 2021 |
|
Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7
CR Banerji, PS Zammit |
EMBO Molecular Medicine | 2021 |
|
Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update
T Schätzl, L Kaiser, HP Deigner |
Orphanet Journal of Rare Diseases | 2021 |
|
Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy
NY Saad, M Al-Kharsan, SE Garwick-Coppens, GA Chermahini, MA Harper, A Palo, RL Boudreau, SQ Harper |
Nature Communications | 2021 |
|
DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy
E Mocciaro, V Runfola, P Ghezzi, M Pannese, D Gabellini |
Cells | 2021 |
|
Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy
J Cohen, A DeSimone, M Lek, A Lek |
Trends in Molecular Medicine | 2021 |
|
Designed U7 snRNAs inhibit DUX4 expression and improve FSHD-associated outcomes in DUX4 overexpressing cells and FSHD patient myotubes
A Rashnonejad, G Amini-Chermahini, NK Taylor, N Wein, SQ Harper |
Molecular Therapy — Nucleic Acids | 2021 |
|
Genetic Approaches for the Treatment of Facioscapulohumeral Muscular Dystrophy
KR Lim, T Yokota |
Frontiers in pharmacology | 2021 |
|
Current Therapeutic Approaches in FSHD
LH Wang, R Tawil, G Bonne |
Journal of neuromuscular diseases | 2021 |
|
Follistatin-induced muscle hypertrophy in aged mice improves neuromuscular junction innervation and function
CC Iyer, D Chugh, PJ Bobbili, AJ Blatnik, AE Crum, AF Yi, BK Kaspar, KC Meyer, AH Burghes, WD Arnold |
Neurobiology of Aging | 2021 |
|
Canine DUXC: implications for DUX4 retrotransposition and preclinical models of FSHD
C Wong, J Whiddon, A Langford, A Belleville, S Tapscott |
Human Molecular Genetics | 2021 |
|
Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice
Darko Bosnakovski, Ahmed S. Shams, Ce Yuan, Meiricris T. Silva, Elizabeth T. Ener, Cory W. Baumann, Angus Lindsay, Mayank Verma, Atsushi Asakura, Dawn A. Lowe, Michael Kyba |
Journal of Clinical Investigation | 2020 |
|
Mouse models for muscular dystrophies: an overview
M van Putten, EM Lloyd, JC de Greef, V Raz, R Willmann, MD Grounds |
Disease models & mechanisms | 2020 |
|
From Mice to Humans: An Overview of the Potentials and Limitations of Current Transgenic Mouse Models of Major Muscular Dystrophies and Congenital Myopathies
M Sztretye, L Szabó, N Dobrosi, J Fodor, P Szentesi, J Almássy, ZÉ Magyar, B Dienes, L Csernoch |
International journal of molecular sciences | 2020 |
|
The prospects of targeting DUX4 in facioscapulohumeral muscular dystrophy
LF Bouwman, SM van der Maarel, JC de Greef |
Current Opinion in Neurology | 2020 |
|
Therapeutic Strategies Targeting DUX4 in FSHD
LL Gall, E Sidlauskaite, V Mariot, J Dumonceaux |
Journal of Clinical Medicine | 2020 |
|
Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity
TI Jones, GL Chew, P Barraza-Flores, S Schreier, M Ramirez, RD Wuebbles, DJ Burkin, RK Bradley, PL Jones |
Skeletal Muscle | 2020 |
|
Dnmt3b regulates DUX4 expression in a tissue-dependent manner in transgenic D4Z4 mice
LF Bouwman, B den Hamer, EP Verveer, LJ Lerink, YD Krom, SM van der Maarel, JC de Greef |
Skeletal Muscle | 2020 |
|
Cellular and animal models for facioscapulohumeral muscular dystrophy
AM DeSimone, J Cohen, M Lek, A Lek |
Disease models & mechanisms | 2020 |
|
Induction of a local muscular dystrophy using electroporation in vivo: an easy tool for screening therapeutics
A Derenne, A Tassin, TH Nguyen, ED Roeck, V Jenart, E Ansseau, A Belayew, F Coppée, AE Declèves, A Legrand |
Scientific Reports | 2020 |
|
Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease
RS Pearsall, MV Davies, M Cannell, J Li, J Widrick, AW Mulivor, S Wallner, ME Troy, M Spaits, K Liharska, D Sako, R Castonguay, S Keates, AV Grinberg, RN Suragani, R Kumar |
Scientific Reports | 2019 |
|
A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death
D Bosnakovski, MT da Silva, ST Sunny, ET Ener, EA Toso, C Yuan, Z Cui, MA Walters, A Jadhav, M Kyba |
Science Advances | 2019 |
|
RNAscope in situ hybridization-based method for detecting DUX4 RNA expression in vitro
GA Chermahini, A Rashnonejad, SQ Harper |
RNA (New York, N.Y.) | 2019 |
|
Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy
AM DeSimone, J Leszyk, KR Wagner, CP Emerson |
Science Advances | 2019 |
